Clinical Trial

Notice to Convene the Annual General Meeting of Genmab A/S

Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 –…

11 months ago

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…

11 months ago

PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD

PARIS, Feb. 13, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with…

11 months ago

Aetion Named Leader in CB Insights’ Synthetic Patient Data Market Report

NEW YORK, Feb. 12, 2025 /PRNewswire/ -- Aetion, the global leader in real-world evidence (RWE) technology and analytics, has been…

11 months ago

Emmes Group advances data security as ISMS certified ISO compliant

Gold-standard accreditation underscores Emmes Group's commitment to secure and data-rich trials for biotech and pharma partners ROCKVILLE, Md., Feb. 12,…

11 months ago

TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients’ Access to Life-Changing Medicines

Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan.   CAMBRIDGE, Mass., Feb. 12, 2025 /PRNewswire/…

11 months ago

Clearsense Announces Strategic Rebrand and Relocation of Headquarters to Nashville

New market position highlights Clearsense as a leading healthcare data enablement platform, showcasing the transformative value of its solutions NASHVILLE,…

11 months ago

NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update

Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million…

11 months ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control armsPhase 1/2 study (N=60) demonstrated favorable safety…

11 months ago

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with…

11 months ago